Role of serum interleukin-6 in heart failure
DOI:
https://doi.org/10.18203/2349-3933.ijam20183123Keywords:
Cardiovascular disease, Enzyme-linked imunosorbent assay, Heart failure, Inflammatory markersAbstract
Background: A growing body of evidence suggests that inflammation plays the key role in different cardiovascular diseases. But very study has been done so far in relation to serum interleukin-6 in heart failure patients. The aim of the study was to measure serum interleukin-6 in heart failure patients.
Methods: Total 22 heart failure patients and 22 age and sex matched controls were included in this study from August 2015 to June 2016 for serum analysis of interleukin-6.
Results: serum interleukin-6 was significantly [median(IQR) 14.3(26.2) pg/mL] increased in heart failure patients compared to age and sex matched controls [median(IQR) 0(2.4) pg/mL].
Conclusions: Even though little is known about function of interleukin-6 in heart failure patients, this study shows that increased level of IL-6 in heart failure patients plays an important role as a pro-inflammatory marker in development of cardiovascular disease i.e. heart failure.
References
Wainstein MV, Mossmann M, Araujo GN, Gonçalves SC, Gravina GL, Sangalli M, et al. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. Diabetol Metabolic Syndrome. 2017;9(1):67.
Ram Dhungana R, Devkota S, Kumar Khanal M, Gurung Y, Kumar Giri R, Krishna Parajuli R, et al. Prevalence of cardiovascular health risk behaviors in a remote rural community of Sindhuli district, Nepal. BMC Cardiovasc Disord. 2014;14(92):1-8.
Huffman MD, Prabhakaran D. Heart failure: epidemiology and prevention in India. Natl Med J India. 2010;23(5):283-8.
Shrivastava AK, Singh HV, Raizada A, Singh SK. Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction. Excli J. 2015;14:1611-2156.
Tan J, Hua Q, Gao J, Fan ZX. Clinical investigations clinical implications of elevated serum interleukin 6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment Elevation Myocardial Infarction. Clin Cardiol. 2008;31(9):413-8.
Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. Mediators Inflamm. 2013;2013.
Van Kimmenade RRJ, Januzzi JL. Emerging biomarkers in heart failure. Clin Chem. 2012;58(1):127-38.
Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al. Inflammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578-89.
Alwi I, Santoso T, Suyono S, Sutrisna B, Kresno SB. The cut-off point of interleukin-6 level in acute coronary syndrome. Acta Med Indones. 2016;39(4):174-8.
Biswas S, Ghoshal PK, Mandal SC, Mandal N. Relation of anti- to pro-inflammatory cytokine ratios with acute myocardial infarction. Korean J Intern Med. 2010;25(1):44-50.
Hassanzadeh M, Faridhosseini R, Mahini M, Farid-Hosseini F, Ranjbar A, Faridhosseini R. Serum Levels of TNF-α, IL-6, and selenium in patients with acute and chronic coronary artery disease. Iran J Immunol. 2006;3(3):142-5.
Ikeda U, Ohkawa F, Seino Y, Yamamoto K, Hidaka Y, Kasahara T, et al. Serum interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol. 1992;24(6):579-84.
Sendesni R, Lahidheb D, Ayoub M, Grira N, Lafi D, Stambouli N, et al. Correlation between Inflammatory Markers and Lipid Parameters in a Tunisian Coronary Artery Disease Group. 2016;03(05):1-9.
Rajappa M, Sen SK, Sharma A. Role of pro-/anti-inflammatory cytokines and their correlation with established risk factors in South Indians with coronary artery disease. Angiology. 2008;60(4):419-26.
Mahalle N, Mk G, Mv K, Ss N. Association of inflammatory cytokines with traditional and non-traditional cardiovascular risk factors in Indians with known coronary artery disease. Ann Med Health Sci Res. 2014;4(5):706-12.
Mowafy A, El-Akabawy H, Hussein A, Abd A, Hay E. Prognostic value of IL6 in young adults presenting with acute coronary syndrome. Egypt Hear J. 2015;67:151-8.
Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99(16):2079-84.
Plenz G, Fang Z, Tjan TDT, Koenig C, Baba HA, Erren M, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. 2001;415-21.
Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 1999;100(11):1148-50.
Cagli K, Basar FN, Tok D, Turak O, Basar O. How to interpret liver function tests in heart failure patients? Turkish J Gastroenterol. 2015;26(3):197-203.
Hashizume M, Mihara M. IL-6 and lipid metabolism. Inflamm Regen. 2011;31(3):325-33.
Ramos AM, Pellanda LC, Gus I, Portal VL. Inflammatory markers of cardiovascular disease in the elderly. Arq Bras Cardiol. 2009;92(3):233-40.
Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women Women’s Health Aging Study Stefano. Circulation. 2001;103:947-53.
Nijm J, Wikby A, Tompa A, Olsson AG. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol. 2005;95:452-6.
Min X, Lu M, Tu S, Wang X, Zhou C, Wang S, et al. Serum cytokine profile in relation to the severity of coronary artery disease. Biomed Res Int. 2017;2017:1-10.
Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100(8):793-8.
Testa M, Yeh M, Lee P, Berman JW, Lejemtel TH, Fanelli R, Loperfido F. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28(4):964-71.
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 1996;27(5):1201-6.
Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in [atients with chronic heart failure. Circulation. 2000;102:3060-7.
Deswal A, Petersen NJ, Feldman M, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103(16):2055-9.
Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31(2):391-8.
Ikeda U, Ito T, Shimada WKL. Interleukin-6 and Acute Coronary Syndrome. Clin Cardiol. 2001;24:701-4.
Paulus WJ. How are cytokines activated in heart failure?. Eur J Heart Failure. 1999;1(4):309-12.
Mehra VC, Ramgolam VS, Bender JR. Cytokines and cardiovascular disease. J Leukoc Biol. 2005;78:805-18.
